Loading
companiesCompany
Hangzhou Sumgen Biotech
Hangzhou Sumgen Biotech is a China-based biotechnology company running 2 late-stage cancer trials of SG2918 and SG301 in multiple myeloma.
Also called: Hangzhou Sumgen Biotech Co., Ltd.
Overview
Hangzhou Sumgen Biotech, based in Hangzhou, China, is a biotechnology company. Sumgen Biotech is a biotech company focused on innovative drug development in oncology, specialising in antibody drugs including monoclonal antibodies and antibody-drug conjugates. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing SG2918 and SG301 in multiple myeloma. The largest, NCT06508983 (A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients), plans to enrol 360 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Hangzhou, CN
Scorecard
All companies#349of 1244 companies, score 11
- phase 3 +3
- targets +2
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2015
Phase 3monoclonal antibody (humanised anti-CD38, per the sponsor's description; form not stated in the registry record)
SG301 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Sumgen Biotech in phase 3 trials for multiple myeloma, aimed at CD38.
Similar pages
- TargetCD38
Shares SG301, Multiple myeloma.
cancers
drugs
Phase 3monoclonal antibody (humanised anti-CD38, per the sponsor's description; form not stated in the registry record)